Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 600
- Registration Number
- NCT03229200
- Locations
- 🇦🇺
Concord Repatriation General Hospital - Haematology Clinical Trials, Sydney, New South Wales, Australia
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT02902965
- Locations
- 🇨🇿
Fakultní nemocnice Brno, Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králové, Nový Hradec Králové, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czechia
© Copyright 2024. All Rights Reserved by MedPath